VisionGate’s quick, non-intrusive lung cancer test based on 3D cellular imaging helps detect early lung cancer when the chance of cure is the strongest.

VisionGate Leading Research Against Lung Cancer

At the Forefront of Novel Science

VisionGate is a biotechnology company leading the battle against lung cancer in high-risk patients using simple non-invasive testing, 3D cell imaging, and a patented AI-powered cancer detection process.

Our Breakthrough
Technology

VisionGate offers the earliest detections of lung cancer when the chance for a sure is the best. Our quick non-intrusive test is based on 3D cellular imaging and Ai.

Non-Intrusive
Testing

Sputum (phlegm) samples from a deep cough (LuCED° Lung Test) are collected over a three-day period using a take-home test kit.

Patented
Cell-CT™ Imaging

High-resolution 3D images of sputum cells measure hundreds of disease indicators.

AI-Powered
Cancer Detection

AI-classifiers are trained to identify abnormal cells. The result is highly accurate cell classification.

VisionGate
Potential

VisionGate’s intellectual property is comprised of 35 patents with 5 more pending.

Please contact us for investment opportunities.

visiongate potentional 35 patents 51 billion

Our Clinical Partners

Feinber School of Medicine
northwestern university feinberg school of medicine logo